Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
124,60 €
-0,36 %
Neurocrine Biosciences (NBIX) had its price target raised by Canaccord Genuity Group Inc. from $164.00 to $200.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $204.00 to $242.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Leerink Partners from $160.00 to $170.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Wedbush from $166.00 to $176.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Guggenheim. They now have a $175.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Piper Sandler from $190.00 to $207.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Royal Bank Of Canada from $176.00 to $180.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $242.00 to $246.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NBIX) had its price target raised by Truist Financial Corporation from $140.00 to $155.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Royal_Bank_of_Canada in Williams Companies Inc. diskutieren